Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788162 · ClinicalTrials.gov registry record · NA
18616 - Sun Protection Factor Assay
A NA study of Sunscreening Agent, sponsored by Bayer.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02788162: Completed NA study of Sunscreening Agent, sponsored by Bayer.
NCT02788162 is a NA study of Sunscreening Agent that has completed, run by Bayer. The registered enrollment target is 10 participants, below the 23-participant average among 7 other Sunscreening Agent trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02788162, a NA study of Sunscreening Agent, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the Sun Protection Factor efficacy on human skin.
Conditions Studied
Interventions
- DRUG Coppertone (BAY 987517)
Study Locations (1)
New Jersey
- - Union
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2015-10-21 |
| Phase | NA |
What the finished NCT02788162 record still lists
NCT02788162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 23-participant average among 7 other Sunscreening Agent trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Sunscreening Agent appearing as the primary indexed condition, and to 1 intervention - of which Coppertone (BAY 987517) is the first listed.
NCT02788162 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02788162 about?
NCT02788162 is a clinical study titled "18616 - Sun Protection Factor Assay". To evaluate the Sun Protection Factor efficacy on human skin.
What is the current status of trial NCT02788162?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2015-10-19. Estimated completion is 2015-10-21.
What conditions does trial NCT02788162 study?
This clinical trial studies the following conditions: Sunscreening Agent.
What interventions are being tested in trial NCT02788162?
The interventions under investigation include: Coppertone (BAY 987517) (DRUG).
Who is sponsoring clinical trial NCT02788162?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02788162 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sunscreening Agent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18842 - Sun Protection Factor Assay
COMPLETED · NA
-
Sun Protection Factor Assay
COMPLETED · NA
-
Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old
COMPLETED · NA
-
18841- Sun Protection Factor Assay
COMPLETED · NA
-
Sun Protection Factor Assay
COMPLETED · NA
-
18791 - Sun Protection Factor Assay
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI